modelEstrone
Extends from Pharmacolibrary.Drugs.ATC.G.G03CC04.
Information
| name: | Estrone | |
| ATC code: | G03CC04 | route: | oral |
| compartments: | 1 | |
| dosage: | 2 | mg |
| volume of distribution: | 35 | L |
| clearance: | 0.6 | L/h |
| other parameters in model implementation | ||
Estrone is a naturally occurring estrogen and one of the three major endogenous estrogens. It plays a role in the development and maintenance of female reproductive tissues and secondary sexual characteristics. Estrone has been used therapeutically in hormone replacement therapy (HRT) and occasionally in the treatment of menopausal symptoms. Its use has declined due to preferences for other forms of estrogen and potential safety concerns.
Pharmacokinetics
Pharmacokinetics of estrone in healthy adult females following oral administration.
References
Doll, E, et al., & Sarvaideo, JL (2022). Pharmacokinetics of Sublingual Versus Oral Estradiol in Transgender Women. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 28(3) 237–242. DOI:10.1016/j.eprac.2021.11.081 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34781041
Stehman-Breen, C, et al., & Ott, S (2003). Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Kidney international 64(1) 290–294. DOI:10.1046/j.1523-1755.2003.00073.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12787421
Zhang, L, et al., & Shentu, J (2024). Pharmacokinetics and Safety of Estradiol Valerate Tablet and Its Generic: A Phase 1 Bioequivalence Study in Healthy Chinese Postmenopausal Female Subjects. Drug design, development and therapy 18 2891–2904. DOI:10.2147/DDDT.S460681 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39006193
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)